Clinical outcomes of patients receiving long-term fondaparinux for thrombotic antiphospholipid syndrome.

Introduction: Vitamin-K antagonists (VKA) are considered the first-line anticoagulants for thrombotic antiphospholipid syndrome (TAPS), particularly with triple positivity or arterial events. However, thrombotic recurrence remains high despite anticoagulation and other clinical issues may arise. Long-term parenteral anticoagulants may therefore be considered, however little is known about the viability of fondaparinux in this setting.

An Evaluation of Rituximab for Rheumatoid Arthritis.

Editor's note: This is a summary of a nursing care-related systematic review from the Cochrane Library.